Abstract:Recent studies indicated that oligomeric β -amyloid (A β) peptides are more neurotoxic to cells or tissues than A β monomers and fibrils even though the underlying mechanism of the A β -induced toxicity is still elusive. The discovery of inhibitors that can prevent cytotoxic oligomeric A β formation has become one of vital goals for therapeutic drug development for AD. Meanwhile, it is of fundamental importance to investigate and understand the structure of toxic A β oligomeric assembly, the mechanism of the induced cytotoxicity, the inhibitory mode of action, and the structural-activity relationship of inhibiting amyloid oligomerization. Toward this end, a series of 15 novel cyanine-derived A β peptide aggregation inhibitors have been synthesized aiming at investigating the structural-activity properties of these compounds in the role of AD treatment. Fifteen novel carbazole-based cyanine derivatives bearing various functionalized heteroaromatic electron-accepting moieties including pyridinium, benzothiazolium, quinolinium and acridinium have been synthesized for a systematic structure-activity relationships investigation as useful and potent A β peptide aggregation inhibitors. The binding affinity was characterized by dissociation constants derived from fluorescence titration of cyanine compounds against amyloid full-length A β 1-40, A β 1-42 peptides as well as A β fragments of different regions. The inhibitory effect on A β peptide aggregation was investigated with fluorescence, and transmission electron microscopy, and circular dichroism. The bio-viability was evaluated by cell-based and animal studies. Our studies further affirmed the importance of hydrophobic and Ï€-Ï€ stacking interactions for the association of this class of carbazole-based cyanines with A β peptides and fibrils. Slight structural modification alters the binding affinity to the monomeric and aggregated amyloids and hence the inhibition potency. Fifteen newly designed cyanine derivatives for studying the structural/activity properties of the A β binding and A β aggregation inhibition have been developed. Importantly, such slight structural variation also provides a means to tune the biological properties such as cytotoxicity and protection from A β- induced toxicity for potential clinical applications. Remarkably, seven non-toxic cyanine derived inhibitors for A β peptide self-aggregation are identified which shows therapeutic potential for AD treatment.

Structural Optimization and Biological Evaluation of Substituted Bisphenol A Derivatives As Beta-Amyloid Peptide Aggregation Inhibitors.

Design, Synthesis and Biological Evaluation of 2-Styryl-5-hydroxy-4-pyrone Derivatives and Analogues As Multiple Functional Agents with the Potential for the Treatment of Alzheimer's Disease.

Inhibitor discovery targeting the intermediate structure of beta-amyloid peptide on the conformational transition pathway: implications in the aggregation mechanism of beta-amyloid peptide.

Inhibitor discovery targeting the intermediate structure of β-amyloid peptide on the conformational transition pathway: Implications in the aggregation mechanism of β-amyloid peptide

Identification of N-phenyl-3-methoxy-4-pyridinones As Orally Bioavailable H3 Receptor Antagonists and Β-Amyloid Aggregation Inhibitors for the Treatment of Alzheimer's Disease.

Synthesis, Biological Evaluation and Molecular Modeling of Benzofuran Piperidine Derivatives As Aβ Antiaggregant

Design, Synthesis, and Bioactivity of Novel Bifunctional Small Molecules for Alzheimer's disease.

Impact of Alternating Amino Acid Sequences on Beta-Amyloid-induced Neurotoxicity and Neuroinflammation in Alzheimer's Disease.

Design, synthesis and biological evaluation of novel pyrazolinone derivatives as multifunctional ligands for the treatment of Alzheimer's disease

Design, Synthesis, and Biological Evaluation of 2-Arylethenylquinoline Derivatives As Multifunctional Agents for the Treatment of Alzheimer's Disease.

Multitarget-directed Benzylideneindanone Derivatives: Anti-Β-amyloid (aβ) Aggregation, Antioxidant, Metal Chelation, and Monoamine Oxidase B (MAO-B) Inhibition Properties Against Alzheimer's Disease.

Macromolecular and small-molecule modulation of intracellular Aβ42 aggregation and associated toxicity.

Synthesis and Structure−Affinity Relationships of Novel Dibenzylideneacetone Derivatives As Probes for Β-Amyloid Plaques

N-Benzyl, N-phenethyl and N-benzyloxybenzamide derivatives inhibit amyloid-beta (Aβ42) aggregation and mitigate Aβ42-induced neurotoxicity

Design, Synthesis, and Bioevaluation of Benzamides: Novel Acetylcholinesterase Inhibitors with Multi-Functions on Butylcholinesterase, Aβ Aggregation, and Β-Secretase.

POTENT INHIBITORS FOR OLIGOMERIC B-AMYLOID AGGREGATION

Dehydroabietylamine derivatives as multifunctional agents for the treatment of Alzheimer's disease

Design, Synthesis, and Biological Evaluation of 4‐aminopyrimidine or 4,6‐diaminopyrimidine Derivatives As Beta Amyloid Cleaving Enzyme‐1 Inhibitors

Design, Synthesis and Biological Evaluation of 1-Phenyl-ethanone Derivatives for Multi-Targeted Treatment of Alzheimer's Disease

Metallosupramolecular Complex Targeting an Alpha/Beta Discordant Stretch of Amyloid Beta Peptide

Design and Synthesis of New Benzo[d]oxazole-Based Derivatives and Their Neuroprotective Effects on β-Amyloid-Induced PC12 Cells